LobbyingEgenesis lobbying by quarter
Egenesis's latest lobbying report covers Q2 2026, at $60K. The four quarters Q4 2025–Q3 2026 total $130K. Its first report covers Q4 2024; the issues it reports most are Health Issues.
Egenesis
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $130K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2024
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2024 | $50K | 1 |
| Q1 2025 | $110K | 1 |
| Q2 2025 | $110K | 1 |
| Q3 2025 | $80K | 2 |
| Q4 2025 | $10K | 2 |
| Q1 2026 | $60K | 2 |
| Q2 2026 | $60K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$400K · 6 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES4 reports
- SENATE4 reports
- Centers For Medicare and Medicaid Services (CMS)3 reports
- Health Resources & Services Administration (HRSA)3 reports
- Food & Drug Administration (FDA)2 reports
- Health & Human Services, Dept of (HHS)2 reports
Firms it paid
| Firm | ||
|---|---|---|
| Invariant | $270K | 6 quarters |
| King & Spalding | $210K | 4 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| EMILY DUHOVNY SILVERBERG | Apr 2025-May 2026 Deputy Chief of Staff/Legislative Director Jan 2021-Apr 2025 Legislative Director May 2014-Jan 2020 Senior Legislative/Policy Advisor Jan 2013-April 2018 Staff/Legislative Assistant Sep 2012-Jan 2013 Congressional Intern. | Q2 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/19for Q2 | King & Spalding | $60K |
| 04/20for Q1 | King & Spalding | $60K |
| 03/20for Q1 | Invariant | Under $5,000 |
| 01/19for Q4 2025 | King & Spalding | $10K |
| 01/18for Q4 2025 | Invariant | Under $5,000 |
| 25/10/19for Q3 2025 | King & Spalding | $80K |
| 25/10/19for Q3 2025 | Invariant | Under $5,000 |
| 25/08/29for Q3 2025 | King & Spalding | Under $5,000 |
| 25/07/17for Q2 2025 | Invariant | $110K |
| 25/04/21for Q1 2025 | Invariant | $110K |
| 25/01/20for Q4 2024 | Invariant | $50K |
| 25/01/03for Q4 2024 | Invariant | Under $5,000 |